3/17
06:55 pm
ewtx
Why Edgewise Therapeutics Stock Topped the Market on Tuesday [Yahoo! Finance]
Low
Report
Why Edgewise Therapeutics Stock Topped the Market on Tuesday [Yahoo! Finance]
3/17
10:46 am
ewtx
Edgewise Therapeutics (EWTX) had its price target raised by JPMorgan Chase & Co. from $34.00 to $45.00. They now have an "overweight" rating on the stock.
Low
Report
Edgewise Therapeutics (EWTX) had its price target raised by JPMorgan Chase & Co. from $34.00 to $45.00. They now have an "overweight" rating on the stock.
3/17
08:25 am
ewtx
Edgewise Therapeutics (EWTX) had its "outperform" rating reaffirmed by Wedbush. They now have a $32.00 price target on the stock.
Low
Report
Edgewise Therapeutics (EWTX) had its "outperform" rating reaffirmed by Wedbush. They now have a $32.00 price target on the stock.
3/16
03:46 am
ewtx
Why Edgewise Therapeutics (EWTX) Is Up 6.4% After Long-Term Sevasemten Becker Data - And What's Next [Yahoo! Finance]
Low
Report
Why Edgewise Therapeutics (EWTX) Is Up 6.4% After Long-Term Sevasemten Becker Data - And What's Next [Yahoo! Finance]
3/15
11:13 pm
ewtx
Edgewise Therapeutics Talks Phase III Becker Readout, EDG-7500 HCM Data Due in Q2 at Conference [Yahoo! Finance]
Low
Report
Edgewise Therapeutics Talks Phase III Becker Readout, EDG-7500 HCM Data Due in Q2 at Conference [Yahoo! Finance]
3/10
01:13 pm
ewtx
Edgewise Therapeutics (EWTX) was given a new $46.00 price target by Raymond James Financial, Inc..
Low
Report
Edgewise Therapeutics (EWTX) was given a new $46.00 price target by Raymond James Financial, Inc..
3/10
07:21 am
ewtx
Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up [Yahoo! Finance]
Low
Report
Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up [Yahoo! Finance]
3/10
07:00 am
ewtx
Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up
Low
Report
Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up
3/4
08:00 am
ewtx
Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026
Low
Report
Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026
3/3
08:13 am
ewtx
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference [Yahoo! Finance]
Low
Report
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference [Yahoo! Finance]
3/3
08:00 am
ewtx
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference
Low
Report
Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference
3/2
09:30 am
ewtx
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Low
Report
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
2/28
05:57 am
ewtx
Edgewise Therapeutics (EWTX) was upgraded by HC Wainwright to "strong-buy".
Low
Report
Edgewise Therapeutics (EWTX) was upgraded by HC Wainwright to "strong-buy".
2/28
01:30 am
ewtx
Low
Report
2/26
05:03 pm
ewtx
Edgewise Therapeutics (EWTX) had its "outperform" rating reaffirmed by Evercore Inc.
Low
Report
Edgewise Therapeutics (EWTX) had its "outperform" rating reaffirmed by Evercore Inc.
2/26
12:11 pm
ewtx
Edgewise Therapeutics (EWTX) was given a new $25.00 price target by Stifel Nicolaus.
Low
Report
Edgewise Therapeutics (EWTX) was given a new $25.00 price target by Stifel Nicolaus.
2/26
08:35 am
ewtx
Assessing Edgewise Therapeutics (EWTX) Valuation After Strong Multi-Year Returns And Recent Share Price Momentum [Yahoo! Finance]
Low
Report
Assessing Edgewise Therapeutics (EWTX) Valuation After Strong Multi-Year Returns And Recent Share Price Momentum [Yahoo! Finance]
2/26
08:19 am
ewtx
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs [Yahoo! Finance]
Low
Report
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs [Yahoo! Finance]
2/26
08:00 am
ewtx
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs
Low
Report
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs
2/15
01:09 am
ewtx
Edgewise Therapeutics (NASDAQ:EWTX) was upgraded by analysts at
Wall Str
Low
Report
Edgewise Therapeutics (NASDAQ:EWTX) was upgraded by analysts at
Wall Str
2/9
10:58 am
ewtx
Edgewise Therapeutics (NASDAQ:EWTX) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Medium
Report
Edgewise Therapeutics (NASDAQ:EWTX) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
2/7
02:07 am
ewtx
Edgewise Therapeutics (NASDAQ:EWTX) was downgraded by analysts at
Wall S
Medium
Report
Edgewise Therapeutics (NASDAQ:EWTX) was downgraded by analysts at
Wall S
2/5
08:15 am
ewtx
Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 [Yahoo! Finance]
Medium
Report
Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 [Yahoo! Finance]
2/5
08:00 am
ewtx
Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026
Medium
Report
Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026
2/2
08:00 am
ewtx
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
Low
Report
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules